Laboratorios Farmaceuticos Rovi stock forecast
Laboratorios Farmaceuticos Rovi (41L) Stock Forecast & Price Target
41L Analyst Ratings
41L Stock 12 Month Forecast
Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| James Vane | Jefferies | €83.50→€64.20 | hold | -8.94%Downside | Reiterated | 05/13/26 | ||
| Pablo de Renteria | Kepler Capital | €90→€83 | buy | 17.73%Upside | Reiterated | 05/06/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| James VaneJefferies | HoldReiterated€83.50→€64.20 | 05/13/26 | -8.94%Downside | ||
| Pablo de RenteriaKepler Capital | BuyReiterated€90→€83 | 05/06/26 | 17.73%Upside |
Best Analysts Covering Laboratorios Farmaceuticos Rovi
Copying Pablo de Renteria's trades and holding each position for 3 Months would result in 47.83% of your transactions generating a profit, with an average return of -3.06% per trade.
Copying Pablo de Renteria's trades and holding each position for 1 Year would result in 52.17% of your transactions generating a profit, with an average return of +3.21% per trade.
Copying Pablo de Renteria's trades and holding each position for 2 Years would result in 73.91% of your transactions generating a profit, with an average return of +9.87% per trade.
41L Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 0 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 2 | 0 | 0 | 0 | 0 |
In the current month, 41L has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 41L average Analyst price target in the past 3 months is ―.
41L Financial Forecast
41L Earnings Forecast
Next quarter’s earnings estimate for 41L is EUR 1.53 with a range of ― to ―. The previous quarter’s EPS was EUR 1.53. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.
41L Sales Forecast
Next quarter’s sales forecast for 41L is EUR 266.01M with a range of ― to ―. The previous quarter’s sales results were EUR 266.01M. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.
